Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 69

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 5
Chunk 69
---
 2000 we financed our operations primarily through borrowings from two of our then directors, which were repaid from the proceeds of such offering. Since our initial public offering, we have financed our operations primarily through sales of equity securities, proceeds from the exercise of options, government grants, licensing and research collaborations and interest earned on investments.

In November 2023, we received commitments for a capital raising of $4.8 million by means of a private placement. The private placement was conducted at 0.0035 per new share. For every new share issued, one free attaching short-dated option was issued.

41

In February 2024, we received commitments for a capital raising of $3.25 million by means of a placement. The placement was conducted at 0.0038 per new share. For every three new share issued, one free attaching listed option was issued.

In February 2024, we received commitments for a capital raising of $2 million by means of a Securities Purchase Plan. The number of securities issued to the participants on 2 February 2024 following the scaleback and pursuant to ASX Listing Rule 7.1, and which were within the volumes approved by shareholders at the EGM, are:

●   571,428,556 SPP Shares at A$0.0035 (0.35 Australian cents)
                   per SPP Share (ASX:ATH); and               
--------------------------------------------------------------

●   571,428,556 unlisted Short-Dated Options (each with an exercise 
    price of A$0.007, expiring on 31 August 2024) (ASX: ATHAAI); and
--------------------------------------------------------------------

●   190,476,123 listed Long-Dated Options (each with an exercise
     price of A$0.01, expiring on 31 August 2026) (ASX: ATHO).  
----------------------------------------------------------------

On February 15, 2024 we entered into a sales agreement with JonesTrading Institutional Services LLC, or JonesTrading, under which we may issue and sell ADSs from time to time in “at the market offerings” pursuant to a Prospectus Supplement. Subject to the terms and conditions of the sales agreement, JonesTrading agreed to use its commercially reasonable efforts to sell the ADSs from time to time as agent, based upon our instructions. JonesTrading is entitled to a commission at a fixed commission rate equal to 3.0% of the gross sales price per shares sold. On February